Apimeds Pharmaceuticals US, Inc. stock analysis
Want to see APUS full AI Analyst Report?
Apimeds Pharmaceuticals US, Inc. (APUS) Stock Price & Analysis
APUS Stock Chart & Stats
- Day’s Range
- $1.51 - $1.77
- 52-Week Range
- $1.51 - $59.70
- Previous Close
- $1.74
- Volume
- N/A
- Average Volume (3M)
- 123.82K
- Market Cap
- $2.96M
- Enterprise Value
- $24.00M
- Total Cash (Recent Filing)
- $17.91K
- Total Debt (Recent Filing)
- $9.61M
- Price to Earnings (P/E)
- ―
- Beta
- 2.44
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Modest debt relative to equity gives APUS a stronger financial cushion than its earnings profile would suggest. This reduces near-term interest and refinancing pressure and preserves some flexibility to fund commercialization while the company works toward a more sustainable operating model.
High Gross Margin
The very high reported gross margin indicates that the emerging revenue base has attractive economics before operating costs. If APUS can scale demand and control its substantial overhead, this structure could support meaningful incremental contribution and improve the path toward eventual profitability.
Blockchain Infrastructure Expansion
The BlockAssure agreement broadens APUS’s operating exposure into insurance and reinsurance infrastructure, including development, hosting, security audits and maintenance. That creates a multi-year service relationship and could establish a durable technology role if milestones and continued operations are delivered successfully.
Bears Say
Severe Unprofitability
APUS’s current revenue base is far too small to absorb its operating cost structure, leaving the company deeply unprofitable despite strong gross margin. Persistent losses weaken retained capital and make future improvement dependent on rapid commercialization, disciplined spending, or additional financing.
Persistent Cash Burn
Negative operating and free cash flow show that APUS is not yet funding operations internally. Continued burn can consume its balance-sheet cushion and require further financing before revenues scale, creating ongoing capital-allocation pressure and potentially limiting investment in its growth initiatives.
Funding And Dilution Risk
The history of negative equity and changing equity levels suggests that the present balance-sheet cushion has not eliminated funding dependence. If losses continue, APUS may need external capital, and the pack specifically identifies further dilution as a risk to existing shareholders.
Apimeds Pharmaceuticals US, Inc. News
APUS FAQ
What was Apimeds Pharmaceuticals US, Inc.’s price range in the past 12 months?
What is Apimeds Pharmaceuticals US, Inc.’s market cap?
When is Apimeds Pharmaceuticals US, Inc.’s upcoming earnings report date?
How were Apimeds Pharmaceuticals US, Inc.’s earnings last quarter?
Is Apimeds Pharmaceuticals US, Inc. overvalued?
Does Apimeds Pharmaceuticals US, Inc. pay dividends?
What is Apimeds Pharmaceuticals US, Inc.’s EPS estimate?
How many shares outstanding does Apimeds Pharmaceuticals US, Inc. have?
What happened to Apimeds Pharmaceuticals US, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Apimeds Pharmaceuticals US, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vinod Menon
- Employees
- 7
- Website
- www.mindwavedao.com
- Address
- 100 Matawan Rd, Matawan, NJ, 07747, US
Apimeds Pharmaceuticals US, Inc. (APUS) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 1 | 14 |
| Technical Analysis | 7 | 1 | 2 |
| Moving Averages | 0 | 0 | 12 |












